MedImmune Inc.

One MedImmune Way

Year founded: 1988

Industry: Biotechnology

Post 200 Category: Top 125 Companies

Revenue: $1.14 Billion

Net Income/Loss: ($3,800,000.00)

Earnings per share: ($0.02)

Dividend: n/a

Stockholder equity: $1.67 Billion

Auditor: PricewaterhouseCoopers LLP

Stock: MEDI

Assets: $2.56 Billion

Market capitalization: $6.31 Billion

52-week high: 28.7 10/29/2004

52-week low: 21.7 8/10/2004

Chairman: Wayne T. Hockmeyer

CEO: David M. Mott

Employees: 1976

Local employees: 1060

Description: MedImmune may be the Washington area's most successful biotechnology company, with three products on the market and sales of more than $1 billion.

Developments: As much as chief executive David M. Mott would like investors, analysts and reporters to focus on the firm's four other products, the spotlight on MedImmune continues to be its difficulties with the nasal flu vaccine FluMist. After a disastrous launch during the 2003-2004 flu season — it sold fewer than 500,000 of 4 million doses — MedImmune lowered expectations for FluMist, saying the product wouldn't be a meaningful contributor to its bottom line until an improved version hits the market in 2007. MedImmune executives hope the new version wins wider regulatory approval; the current version is approved for only healthy adults ages 5 through 49. But just as the company was succeeding in lowering hopes for FluMist, expectations soared in the fall, when Chiron Corp. announced that it could not ship nearly half of the U.S. supply of conventional flu shots because of manufacturing problems in England. All eyes were on MedImmune to step in and win customers for its vaccine. But MedImmune, which had planned to put about 1 million doses on the market, could produce only 2 million more because of the lengthy manufacturing process for flu vaccines. In the end, the federal government secured millions of extra flu shots from elsewhere, the flu season was mild, healthy adults stayed away from vaccines altogether, and the country was left with a vaccine surplus, not a shortage. MedImmune said it had expected to sell 1.7 million doses. MedImmune tries to remind investors that it has products other than FluMist. Its blockbuster drug is Synagis, which prevents certain viral infections in babies. The firm sold $942.3 million of Synagis in 2004, up from $849.3 million the year before. The firm is also wrapping up human trials on a new generation of Synagis called Numax. MedImmune also has patients enrolled in advanced human studies on treatments for prostate cancer and melonoma. The firm, with partner GlaxoSmithKline, is working to develop a vaccine against human papillomavirus (HPV), which causes most cases of cervical cancer.

Executive Compensation
President and CEO: David M. Mott
Total Cash: $1,941,667.00
Total Compensation: $13,002,351.00

President, Research and Development: James F. Young
Total Cash: $945,833.00
Total Compensation: $3,895,349.00

Chairman: Wayne T. Hockmeyer
Total Cash: $820,833.00
Total Compensation: $3,770,349.00